Valuation: Virbac

Market Cap 2.84B 3.27B 2.64B 2.43B 4.59B 311B 4.64B 31.06B 12.19B 156B 12.3B 12.03B 516B P/E 2026 *
16.6x
P/E 2027 * 15x
Enterprise Value 2.96B 3.42B 2.76B 2.54B 4.8B 325B 4.85B 32.45B 12.74B 163B 12.85B 12.56B 539B EV / Sales 2026 *
1.91x
EV / Sales 2027 * 1.77x
Free-Float
49.03%
Yield 2026 *
0.51%
Yield 2027 * 0.6%
1 day+1.78%
1 week-0.74%
Current month-0.30%
1 month+4.17%
3 months-7.03%
6 months-2.46%
Current year-3.30%
1 week 331
Extreme 331
338.5
1 month 310.5
Extreme 310.5
344.5
Current year 310.5
Extreme 310.5
381
1 year 297
Extreme 297
381
3 years 243
Extreme 243
392
5 years 220.5
Extreme 220.5
440.5
10 years 102.48
Extreme 102.479
440.5
Manager TitleAgeSince
Chief Executive Officer 46 31/08/2025
Chief Executive Officer 50 26/09/2024
Chief Operating Officer 64 31/12/2021
Director TitleAgeSince
Chairman 61 31/03/2006
Director/Board Member 68 27/07/2010
Director/Board Member 65 04/09/2017
Change 5-day change 1-year change 3-year change Capi.($)
+1.78%-0.74% - - 3.27B
-2.17%-4.54%-49.09%-58.36% 31.19B
+2.42%-0.64%+84.65%+125.06% 13.1B
+0.12%+1.68%-15.25%+1.08% 3.85B
+1.33%+0.44%+4.73%+22.06% 3.27B
-1.27%+14.29%+50.34%+29.41% 2.14B
+2.93%+1.74%+11.43%+28.10% 1.9B
-1.59%-2.54%+35.43%+136.75% 1.46B
+2.43%+13.33%-16.16%-2.90% 1.22B
-0.46%+1.56%-14.99%-46.29% 986M
Average +0.50%+1.15%+10.12%+26.10% 6.57B
Weighted average by Cap. -0.60%-2.11%-5.39%+2.74%

Financials

2026 *2027 *
Net sales 1.55B 1.79B 1.45B 1.33B 2.51B 170B 2.54B 16.99B 6.67B 85.2B 6.73B 6.58B 282B 1.65B 1.9B 1.54B 1.41B 2.67B 181B 2.7B 18.04B 7.08B 90.49B 7.14B 6.99B 300B
Net income 171M 198M 160M 147M 277M 18.79B 280M 1.87B 736M 9.4B 742M 726M 31.13B 190M 219M 177M 163M 307M 20.81B 310M 2.08B 815M 10.41B 822M 804M 34.48B
Net Debt 127M 146M 118M 109M 205M 13.92B 207M 1.39B 545M 6.96B 550M 538M 23.06B 75.16M 86.78M 70.06M 64.44M 122M 8.25B 123M 823M 323M 4.13B 326M 319M 13.67B
Logo Virbac
Virbac specializes in the research, production and marketing of veterinary medicines. Net sales break down by family of products as follows: - pet medications (60.7%): pest control drugs, vaccines, antibiotics, anesthetics, anti-inflammatory drugs, mouth/dental care products, ophthalmologic and dermatological products intended for dogs, cats, horses, birds, rodents, etc. The group also offers foods and electronic identification chips; - livestock medications (39.3%): pest control drugs and antibiotics intended for cattle, sheep, pigs, poultry, etc. Net sales are distributed geographically as follows: Europe (41.6%), Latin America (15.2%), North America (13.6%), India/Africa/Middle East (12.2%), Eastern Asia (10.5%) and Pacific (6.9%).
Employees
6,442
Date Price Change
06/08/26 337.00 +0.15%
05/08/26 €336.50 +0.75%
04/08/26 €334.00 -1.18%
03/08/26 €338.00 0.00%
31/07/26 €338.00 -0.44%
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
338.50EUR
Average target price
411.88EUR
Spread / Average Target
+21.68%

Quarterly revenue - Rate of surprise